AU2016340098B2 - Combination therapy for treating malignancies - Google Patents

Combination therapy for treating malignancies Download PDF

Info

Publication number
AU2016340098B2
AU2016340098B2 AU2016340098A AU2016340098A AU2016340098B2 AU 2016340098 B2 AU2016340098 B2 AU 2016340098B2 AU 2016340098 A AU2016340098 A AU 2016340098A AU 2016340098 A AU2016340098 A AU 2016340098A AU 2016340098 B2 AU2016340098 B2 AU 2016340098B2
Authority
AU
Australia
Prior art keywords
azacitidine
compound
day
idh2
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016340098A
Other languages
English (en)
Other versions
AU2016340098A1 (en
Inventor
Samuel V. Agresta
Vivek Saroj Kumar Chopra
Jorge Dimartino
Laurie A. Kenvin
Robert Douglas Knight
Kyle Macbeth
Krishnan VISWANADHAN
Qiang Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Celgene Corp
Original Assignee
Laboratoires Servier SAS
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS, Celgene Corp filed Critical Laboratoires Servier SAS
Publication of AU2016340098A1 publication Critical patent/AU2016340098A1/en
Assigned to LES LABORATORIES SERVIER, CELGENE CORPORATION reassignment LES LABORATORIES SERVIER Request for Assignment Assignors: AGIOS PHARMACEUTICALS, INC., CELGENE CORPORATION
Application granted granted Critical
Publication of AU2016340098B2 publication Critical patent/AU2016340098B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016340098A 2015-10-15 2016-10-14 Combination therapy for treating malignancies Active AU2016340098B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242218P 2015-10-15 2015-10-15
US62/242,218 2015-10-15
PCT/US2016/057102 WO2017066611A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Publications (2)

Publication Number Publication Date
AU2016340098A1 AU2016340098A1 (en) 2018-05-10
AU2016340098B2 true AU2016340098B2 (en) 2022-06-02

Family

ID=57219007

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016340098A Active AU2016340098B2 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Country Status (16)

Country Link
US (2) US10695352B2 (enExample)
EP (1) EP3362070B1 (enExample)
JP (1) JP6895956B2 (enExample)
KR (1) KR102701893B1 (enExample)
CN (1) CN108601787B (enExample)
AU (1) AU2016340098B2 (enExample)
BR (1) BR112018007447B1 (enExample)
CA (1) CA3002029A1 (enExample)
CL (1) CL2018000955A1 (enExample)
EA (1) EA036129B1 (enExample)
ES (1) ES2862730T3 (enExample)
IL (1) IL258580B (enExample)
MX (1) MX381582B (enExample)
SG (2) SG11201802964QA (enExample)
WO (1) WO2017066611A1 (enExample)
ZA (1) ZA201802420B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9986928B2 (en) 2013-12-09 2018-06-05 Medtronic, Inc. Noninvasive cardiac therapy evaluation
CA2942072C (en) 2014-03-14 2022-07-26 Agios Pharmaceuticals, Inc. Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
IL258684B2 (en) 2015-10-15 2023-04-01 Agios Pharmaceuticals Inc Combination therapy including an isocitrate dehydrogenase (1idh) inhibitor for use in the treatment of acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of 1idh
RS62829B1 (sr) * 2015-10-15 2022-02-28 Servier Lab Kombinovana terapija za lečenje maligniteta
US10905692B2 (en) 2015-10-15 2021-02-02 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
US11219769B2 (en) 2016-02-26 2022-01-11 Medtronic, Inc. Noninvasive methods and systems of determining the extent of tissue capture from cardiac pacing
US11389454B2 (en) 2016-09-07 2022-07-19 Celgene Corporation Tablet compositions
US11229653B2 (en) 2017-05-05 2022-01-25 Celgene Corporation Methods of treatment of myeloproliferative neoplasm
BR112019026378A2 (pt) * 2017-06-12 2020-07-21 Agios Pharmaceuticals, Inc. métodos de tratamento de tumores cerebrais usando terapia de combinação
JP7305613B2 (ja) * 2017-07-09 2023-07-10 バイオサイト リミテッド 併用がん療法
US11285312B2 (en) 2018-03-29 2022-03-29 Medtronic, Inc. Left ventricular assist device adjustment and evaluation
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US12215094B2 (en) 2018-11-02 2025-02-04 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
US11697025B2 (en) 2019-03-29 2023-07-11 Medtronic, Inc. Cardiac conduction system capture
SG11202110702WA (en) * 2019-04-29 2021-11-29 Immunogen Inc Therapeutic combinations comprising anti-cd123 immunoconjugates
BR112021025375A2 (pt) 2019-06-20 2022-02-01 Celgene Corp Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para tratamento de leucemia ou síndrome mielodisplástica
US11497431B2 (en) 2019-10-09 2022-11-15 Medtronic, Inc. Systems and methods for configuring cardiac therapy
US12201843B2 (en) 2019-10-09 2025-01-21 Medtronic, Inc. Synchronizing external electrical activity
JP2023503842A (ja) 2019-11-14 2023-02-01 セルジーン コーポレーション がんを処置するための小児用製剤
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途
US20240229156A1 (en) * 2021-03-12 2024-07-11 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017821A2 (en) * 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
DE69831335T3 (de) 1997-06-06 2015-01-15 Depomed, Inc. Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
MY161593A (en) * 2008-05-15 2017-04-28 Celgene Corp Oral formulations of cytidine analogs and methods of use thereof
CA2725295C (en) * 2008-06-09 2016-11-08 Cyclacel Limited Combination of sapacitabine (cndac) and dna methyltransferase inhibitors such as decitabine and procaine
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
WO2011050211A2 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
KR101987861B1 (ko) * 2011-11-03 2019-06-11 밀레니엄 파머슈티컬스 인코퍼레이티드 Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여
CA2860623A1 (en) 2012-01-06 2013-07-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
SG11201600058XA (en) 2013-07-11 2016-02-26 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
KR20170057411A (ko) 2014-09-29 2017-05-24 아지오스 파마슈티컬스 아이엔씨. 치료적 활성 화합물 및 이들의 사용 방법
KR102628370B1 (ko) 2015-02-04 2024-01-24 르 라보레또레 쎄르비에르 치료적 활성 화합물 및 이들의 사용 방법
AU2016303614A1 (en) 2015-08-05 2018-02-15 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
US10905692B2 (en) 2015-10-15 2021-02-02 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
MA43374A (fr) 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
EP3419593B1 (en) 2016-02-26 2022-03-23 Celgene Corporation Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017821A2 (en) * 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
CA3002029A1 (en) 2017-04-20
US20210100805A1 (en) 2021-04-08
BR112018007447A2 (en) 2018-10-23
KR102701893B1 (ko) 2024-09-03
BR112018007447B1 (pt) 2023-12-05
WO2017066611A1 (en) 2017-04-20
US20180303840A1 (en) 2018-10-25
US10695352B2 (en) 2020-06-30
JP6895956B2 (ja) 2021-06-30
MX381582B (es) 2025-03-12
KR20180064529A (ko) 2018-06-14
NZ741433A (en) 2024-07-26
CL2018000955A1 (es) 2018-09-14
ES2862730T3 (es) 2021-10-07
ZA201802420B (en) 2020-08-26
JP2018535951A (ja) 2018-12-06
EA201890961A1 (ru) 2018-11-30
MX2018004599A (es) 2018-09-21
CN108601787A (zh) 2018-09-28
EP3362070B1 (en) 2021-01-27
EA036129B1 (ru) 2020-10-01
EP3362070A1 (en) 2018-08-22
SG10201912869WA (en) 2020-02-27
CN108601787B (zh) 2022-07-29
IL258580B (en) 2021-05-31
SG11201802964QA (en) 2018-05-30
AU2016340098A1 (en) 2018-05-10
IL258580A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
AU2016340098B2 (en) Combination therapy for treating malignancies
EP3419593B1 (en) Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia
EP3383400B1 (en) Methods of treatment of malignancies
AU2016338557B2 (en) Combination therapy for treating malignancies
US10905692B2 (en) Combination therapy for treating malignancies
EP3493809B1 (en) Enasidenib for treatment of myelodysplastic syndrome

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CELGENE CORPORATION

Free format text: FORMER APPLICANT(S): AGIOS PHARMACEUTICALS, INC.; CELGENE CORPORATION

Owner name: LES LABORATORIES SERVIER

Free format text: FORMER APPLICANT(S): AGIOS PHARMACEUTICALS, INC.; CELGENE CORPORATION

TH Corrigenda

Free format text: IN VOL 36 , NO 20 , PAGE(S) 2696 UNDER THE HEADING ASSIGNMENTS BEFORE GRANT, SECTION 113 - 2016 UNDER THE NAME LES LABORATORIES SERVIER AND CELGENE CORPORATION. APPLICATION NO. 2016340098, UNDER INID (71) CORRECT THE CO-APPLICANT TO LES LABORATOIRES SERVIER

FGA Letters patent sealed or granted (standard patent)